host top manag sever meet earlier week provid
compel argument growth key hematolog immunolog portfolio
potenti support strateg acquisit might involv new therapeut
area stock clearli reflect growth prospect therefor view
current share price buy opportun
assum manag expect hematolog immunolog franchis
realiz tandem modest success franchis manag
believ deliv growth even extrem level humira
biosimilar competit global specif expect ex
believ ultim retain one-third peak ou humira sale
impli less risk foreign market foreign market includ
australia brazil canada japan patent protect reassur
consid one abbv newer drug could gener revenu
 cours much larger obstacl also much time establish
grow new product provid off-set investor apprehens transit
like linger lessen new product regulatori commerci mileston
achiev expect year new product establish
market leverag driven humira formulari posit roughli
believ imbruvica sale power greater use cll data
share stand could grow tandem cumul
impact patient stay therapi longer low singl digit market growth abbv
guidanc peak imbruvica sale look achiev estim
competit landscap materi least far imbruvica transitit
venclexta take cll base strike data venclexta
boost approv aml expect soon agre venetoclax
aml data good becom standard care transplant inelig
patient wildcard venclexta potenti use multipl myeloma late stage data
multipl myeloma due replic earli data venclexta could
becom player new market abbv guidanc peak venclexta sale
well estim assum approv aml multipl
myeloma data meet bullish expect guidanc could achiev venclexta
share asset roch
upadacitinib file ra rizankizunab file psoriasi two key
asset immunolog portfolio receiv posit review
cowen annual therapeut confer last month upadacitinib oral jak
inhibitor underpin solid efficaci safeti data addit possibl indic
includ uc/crohn atop dermat receiv breakthrough design
peg peak sale forecast sale risankizumab
dose month standout efficaci psoriasi also studi crohn uc
peg peak sale forecast sale
pleas see page report import disclosur
provid long-term guidanc expect humira appear
solid foot forese futur competit posit
hepat segment oncolog compani pipelin promis
agent opportun upward revis sever front stock
attract valu versu group overal attribut argu purchas
upadacitinib /eu file ra
risankizumab approv psoriasi
orilissa uptak endometriosi uterin
venclexta approv aml
humira sale
humira biosimilar eros less
especi oncolog
humira biosimilar gain traction
quickli eu and/or launch
global biopharmaceut compani product use treat rheumatoid
chronic kidney diseas among other humira ra crohn domin
product repres total sale profit also pipelin
compound indic phase ii phase develop
believ orilissa could gener peak sale endometriosi
roll current anoth uterin fibroid orilissa sale forecast
state orilissa formulari coverag earli next
year seem terrif given roll potenti contribut
time frame mid-stag candid neurosci oncolog
long-term aspir build addit therapeut vertic within
compani diseas view good fit although less interest fibrosi
specif ipf product layer top venclexta aml area
updat model post result meet manag
ep peg vs guidanc sale
consist guidanc ep estim increas
consist manag double-digit guidanc although sale
clip ep peg increas
although sale reduc sale reduct almost entir
attribut lower hep sale admittedli tough predict given uniqu
patient dynam ep compound-annual-growth-rate although
growth rate still forecast ep declin howev
state earlier manag believ grow throughout time
certainli mani opportun upsid
compani data cowen compani
compani data cowen compani
ww foreign lc ex foreign sale report portion foreign leuprolid foreign lc ex leuprolid foreign lc ex cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
ww ip expect hold till post settlement sever other launch later humira biosimilar launch eu declin year expect foreign lc ex ra pa crohn psoriasi jai uc uveiti hshumira adalimumab anti-tnf mab guidanc approach guidanc peak record sale foreign sale report includ sale total portion foreign record share ou profitsimbruvica approv hematolog cancer pcyc acq close acquir solvay pacrealipas enzym replac pancreat insufficiencysynthroid steadi sale gener difficult formul synthroid levothyroxin overact thyroidlupron leuprolid line extens support foreign lc ex leuprolid gener avail lupron still lead market mo depotsynagi foreign lc ex human mab bind f-protein rsvdepakot divalproex acid seizur control bipolar mania ir patent expir er patent expir cowen
compani data cowen compani
 patent expir maintain share via servic foreign lc ex induct mainten gener anesthesiaultane/sevofluoran flourin isopropyl ether anesthesiaandrogel gener form launch franchiseandrogel testosteron gel hypergonad market declinekaletra lopinavir/low-dos ritonavir combo hiv patent exp market em aluvia combo proteas inhibitor foreign lc ex emerg market slow sale declinenorvir patent expir januari inhibit cytochrom metabol pi foreign lc ex ritonavir hiv proteas inhibitor use booster combozemplar teva gener launch foreign lc ex paricalcitol tx secondari hyperparathyroid pt ckftricor/trilipix gener launch gener launch via settlement teva/brl foreign lc ex er niacin rais hdl reduc ldlother includ gross-to-net adjust assum ceas humira patent us includ nimbex vicodin etc emerg mkt growth foreign lc ex cowen
compani data cowen compani
 combin glecaprevir pi pibrentasvir inhibitor hcv dose tablet qd week eign lc ex all-or regimen genotyp ifn-nav hcv patientsmavyret patient without cirrhosi new treatmentviekirax exviera combin paritaprebir/r pi ombitasvir inhibitor dasabuvir non-nuc polymeras inhibitor hcv eign lc ex all-or regimen genotyp ifn-nav hcv patientsviekirax exviera ww guidanc profit roch incom line royalti estimate sale roch condit eu approv eign lc ex approv cll delet r/r cll rituxanvenclexta venetoclax select inhibitor cllorilissa- oral gnrh antagonist partial estrogen suppress endometriosi approv uterin fibroib file partnership neurocrin eign lc ex similar lupron zoladexelagolix hold ww right orilissa gnrh antagonistsrova-t meru sclc mainten complet taho complet eign lc ex stem cell technolog solid tumor target peak salesrova-t stemcentrx acq conting payment close guidanc file june psoriasi ph crohn uc ph ii eign lc ex month bi bi receiv mileston royaltiesduodopa infus directli small intestin via portabl pump like nich product refractori pd eign lc ex market solvay ousduodopa gel formul carbidopa/levodopa parkinson supadacitinib- guidanc ra file ph atop dermat ph ii axspa gca eign lc ex jak inhibitor competit profil ra crohn uc ad cowen
compani data cowen compani
 partner record profit record royalti ex-u foreign lc ex elotuzumab antibodi multipl myeloma r/r mm foreign lc ex trial fail glioblastoma filingveliparib bid oral dose cross bbb foreign lc ex parp inhibitor ovarian cancer phase zinbryta foreign lc ex fx zinbryta daclizumab withdrawn global march foreign lc ex foreign lc ex guidanc annual revenu growth cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
